Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method for identifying a human as having an increased risk for psoriasis, the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene SLC22A4 as represented by position 101 of SEQ ID NO:108 or its complement by contacting said nucleic acid with an allele-specific primer that specifically hybridizes to G at said position 101 of SEQ ID NO:108 or C at said complement;
b) detecting said G or said C;
c) identifying said human as having an increased risk for psoriasis due to the presence of said G or said C; and
d) administering a therapeutic agent suitable for prevention or treatment of psoriasis to said human.
2. The method of claim 1 , wherein said allele-specific primer comprises SEQ ID NO:133.
3. The method of claim 1 , wherein said testing comprises allele-specific amplification, and further wherein said detecting comprises detecting the presence of an amplicon.
4. The method of claim 1 , wherein said allele-specific primer is detectably labeled with a fluorescent dye.
5. The method of claim 1 , wherein said human is homozygous for said G or said C.
6. The method of claim 1 , wherein said human is heterozygous for said G or said C.
7. A method for reducing the risk of psoriasis in a human, the method comprising:
a) receiving an identification of a human as having an increased risk for psoriasis due to a polymorphism in gene SLC22A4 comprising G at position 101 of SEQ ID NO:108 or C at its complement; and
b) administering a therapeutic agent suitable for prevention or treatment of psoriasis to said human.
8. The method of claim 7 , wherein said human is homozygous for said G or said C.
9. The method of claim 7 , wherein said human is heterozygous for said G or said C.
10. A method for reducing the risk of psoriasis in a human, the method comprising:
a) receiving an identification of a human as having a polymorphism in gene SLC22A4 comprising G at position 101 of SEQ ID NO:108 or C at its complement; and
b) administering a therapeutic agent suitable for prevention or treatment of psoriasis to said human.
11. The method of claim 10 , wherein said human is homozygous for said G or said C.
12. The method of claim 10 , wherein said human is heterozygous for said G or said C.